Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with ²²⁵Ac-PSMA-617: Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor Control

Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer

Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration‐resistant prostate cancer who progress after docetaxel and abiraterone treatment